Salt / ingredient
Glimepiride 1mg + Metformin Hydrochloride Sustained Release 500mg + Voglibose 0.3mg
Lowers blood sugar + Controls blood sugar in type-2 diabetes + Controls after-meal blood sugar
MRP data last verified: August 2026. Source: NPPA Pharma Sahi Daam, reproduced under the NPPA copyright policy.
Private-brand substitutes: kam se zyada
More about this medicine
Reference information
About Glimepiride
This information is from US FDA labels, for reference only. Always follow your doctor's advice.
Common side effects
- with glimepiride were hypoglycemia
- dizziness
- asthenia
- headache
- nausea
- to report suspected adverse reactions
- contact zydus pharmaceuticals (usa) inc
Safety advice
- May affect the liver. Tell your doctor if you have liver problems.
- May affect the kidneys. Tell your doctor if you have kidney problems.
- Avoid or limit alcohol while taking this medicine.
- May cause drowsiness. Be careful driving or operating machines.
- Stop use and seek emergency help if you have signs of a severe allergic reaction.
- May cause low blood sugar. Watch for symptoms like shakiness, sweating, confusion.
Uses
- limepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .
- Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.
- Glimepiride tablets are a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 ).
- Limitations of Use: Not for treating type 1 diabetes mellitus or diabetic ketoacidosis ( 1 ).
- is a combination of sitagliptin, a dipeptidyl peptidase-4 (-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
How to take
- ecommended starting dose is 1 or 2 mg once daily.
- Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response.
- Maximum recommended dose is 8 mg once daily ( 2.1 ).
- Administer with breakfast or first meal of the day ( 2.1 ).
- Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment) ( 2.1 ).
Frequently Asked Questions about Glimepiride 1mg + Metformin Hydrochloride Sustained Release 500mg + Voglibose 0.3mg
What is the price of Glimepiride 1mg + Metformin Hydrochloride Sustained Release 500mg + Voglibose 0.3mg in India?
The price of Glimepiride 1mg + Metformin Hydrochloride Sustained Release 500mg + Voglibose 0.3mg in India depends on the manufacturer and channel. Official Government Jan Aushadhi generic rates start at ₹2.34 per unit.Private commercial brands vary from low-cost options to higher-priced branded formulations.
Is a Government Jan Aushadhi generic available for Glimepiride 1mg + Metformin Hydrochloride Sustained Release 500mg + Voglibose 0.3mg?
Glimepiride 1mg + Metformin Hydrochloride Sustained Release 500mg + Voglibose 0.3mg is listed under PMBI Jan Aushadhi (PMBI Code 2207) at ₹23.44 per pack.
How to find lower-cost substitutes for Glimepiride 1mg + Metformin Hydrochloride Sustained Release 500mg + Voglibose 0.3mg?
Search the active salt formulation (Glimepiride 1mg + Metformin Hydrochloride Sustained Release 500mg + Voglibose 0.3mg) on Sasta Parcha to view private-brand substitutes ranked strictly low-to-high by per-unit price. Always consult your prescribing doctor or pharmacist before changing medicine brands.